Cathepsin S in the treatment of liver cell cancer: effects and target therapy

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-RCC-08000279

Enrollment

Unknown

Registered

2008-12-28

Start date

2007-12-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cell cancer

Interventions

Normal group:No intervention

Liver cell cancer group:Cat S, siRNA inhibitor, Cat S antibody

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patient with liver cell cancer and normal volunteer

Exclusion criteria

Exclusion criteria: Liver cell cancer with metastasis

Design outcomes

Primary

Measure	Time frame
Cat S, SMAA, GFAP, Collagen1, AFP;	—

Countries

China

Contacts

Public ContactJing Xu

gxyifuyi@21.cn.com+86 0771 5356557

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026